|
業務類別
|
Biotechnology |
|
業務概覽
|
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain. |
| 公司地址
| 611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 415 655-4168 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.sprucebiosciences.com |
| 員工數量
| 8 |
| Dr. Kirk Ways, M.D.,PhD |
Director and Interim Chief Medical Officer |
-- |
09/04/2026 |
| Mr. Samir M. Gharib |
Chief Financial Officer, Principal Accounting Officer and President |
美元 465.10K |
09/04/2026 |
| Dr. Javier Szwarcberg, M.D. |
Chief Executive Officer and Director |
美元 610.00K |
09/04/2026 |
| Mr. Corwin Dale Hooks |
Chief Commercial Officer |
-- |
09/03/2026 |
|
|
| Mr. Daniel K. Spiegelman |
Independent Director |
09/04/2026 |
| Dr. Kirk Ways, M.D.,PhD |
Director and Interim Chief Medical Officer |
09/04/2026 |
| Mr. Percival Barretto-Ko |
Independent Director |
09/04/2026 |
| Dr. Javier Szwarcberg, M.D. |
Chief Executive Officer and Director |
09/04/2026 |
| Ms. Keli Walbert |
Director |
09/04/2026 |
| Ms. Camilla V. Simpson, M.Sc. |
Independent Director |
09/04/2026 |
| Mr. Michael Grey |
Executive Chairman of the Board |
09/04/2026 |
|
|
|
|
